Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues is an emerging and convincing treatment modality for patients with unresectable, somatostatin-receptor-positive neuroendocrine tumours. Using radiolabelled somatostatin analogues for imaging became the gold standard for staging of neuroendocrine tumours. The somatostatin receptor is strongly over-expressed in most tumours, resulting in high tumour-to-background ratios. Consequently, the next step was to try to treat these patients by increasing the radioactivity of the administered radiolabelled somatostatin analogue in an attempt to bring about tumour cure. Many patients have been treated successfully with this approach, roughly 25% of them achieving objective tumour shrinkage >50%. Serious side-effects have been rare. This article reviews the effectiveness and safety of the different radiolabelled somatostatin analogues used. Furthermore, clinical issues - including indication and timing of therapy - are discussed. Finally, important directions for future research are mentioned to illustrate new strategies for increasing therapy efficacy.

Additional Metadata
Keywords carcinoid tumour, internal radiotherapy, neuroendocrine tumour, radionuclide therapy, somatostatin receptor
Persistent URL dx.doi.org/10.1016/j.beem.2007.01.007, hdl.handle.net/1765/37051
Journal Bailliere's Best Practice & Research. Clinical Endocrinology and Metabolism
Citation
Forrer, F, Valkema, R, Kwekkeboom, D, de Jong, M, & Krenning, E.P. (2007). Peptide receptor radionuclide therapy. Bailliere's Best Practice & Research. Clinical Endocrinology and Metabolism (Vol. 21, pp. 111–129). doi:10.1016/j.beem.2007.01.007